Omadacycline Shows Promise in Phase II Trial for Nontuberculous Mycobacterial Pulmonary Disease
核心洞察
Paratek's omadacycline demonstrated significant bacterial burden reduction in a Phase II trial for nontuberculous mycobacterial pulmonary disease (搜索) caused by Mycobacterium abscessus complex (搜索).
The study showed 76.5% of omadacycline-treated patients experienced decreased culture scores compared to 45.8% of placebo patients, with 53.8% achieving negative cultures at day 84.
Omadacycline addresses a critical unmet need in NTM treatment, where nearly all current therapies are used off-label, and has received FDA fast-track and orphan drug designations.
Dr. Reeti Khare of National Jewish Health presented promising microbiological outcomes from a Phase II, randomized, placebo-controlled trial investigating oral omadacycline in adult patients with nontuberculous mycobacterial pulmonary disease (搜索) (NTM-PD (搜索)) caused by Mycobacterium abscessus complex (搜索) (MABc) at IDWeek 2025 in Atlanta, Georgia.
The exploratory Phase II trial (NCT04922554) enrolled 66 patients aged 18 years or older diagnosed with NTM-PD (搜索) caused by MABc according to Infectious Diseases Society of America/American Thoracic Society guidelines. Patients were randomized to receive either 300mg of oral omadacycline once daily for 84 days or an oral placebo for the same duration.
Significant Bacterial Burden Reduction
The study demonstrated substantial improvements in bacterial burden measures across multiple assessment methods. Using a scoring system based on colony counts on agar plates, omadacycline cultures showed consistent reductions in culture scores at days 28, 56, and 84 compared to placebo cultures. Overall, 76.5% of patients treated with omadacycline experienced a decrease in their culture scores, compared to 45.8% of placebo-treated patients.
Similar results were observed in sputum cultures analyzed in liquid media, with greater reductions in bacterial burden in the omadacycline group. Among omadacycline-treated patients, 73.0% had sputum cultures with growth in liquid medium only, compared to 39.1% of placebo-treated patients, indicating lower bacterial burden.
Most notably, 53.8% of participants in the omadacycline-treated group produced negative sputum cultures at day 84 of treatment, compared to 25.0% of participants in the placebo group. The minimum inhibitory concentrations for omadacycline remained unchanged from baseline to day 84, indicating no development of resistance during the study period.
Addressing Critical Unmet Medical Need
NTM are opportunistic pathogens that cause infections in patients with pre-existing health conditions or compromised immune systems. The most frequent symptoms of NTM-PD (搜索) include cough, fatigue, fever, loss of appetite, shortness of breath, and weight loss. According to GlobalData, prevalent cases of pulmonary NTM are expected to increase by 7.2% in the seven major pharmaceutical markets between 2023 and 2033.
The lack of NTM therapeutics represents one of the biggest unmet needs within the NTM market. Nearly all drugs currently used to treat NTM infections are used off-label, with many being broad-spectrum antibiotics repurposed for NTM treatment.
Regulatory Recognition and Market Position
Paratek's omadacycline, a novel tetracycline derivative, is already marketed in the US and China under the brand name Nuzyra for treating adults with community-acquired bacterial pneumonia (搜索) and acute bacterial skin and skin structure infections (搜索). For the NTM-PD (搜索) indication, omadacycline has received fast-track designation from the US Food and Drug Administration (搜索) (FDA) and orphan drug designation from both the FDA and the European Medicines Agency (搜索).
Key opinion leaders interviewed by GlobalData have expressed positive opinions on the development of oral omadacycline for NTM-PD (搜索), particularly given the lack of novel, effective therapies for this indication. Several US key opinion leaders have acknowledged utilizing omadacycline off-label for treating NTM-PD caused by both Mycobacterium avium complex (搜索) (MAC) and MABc.
The clinical success demonstrated in this Phase II study highlights omadacycline's potential to fulfill a critical unmet need within the NTM market and possibly contribute to increased treatment success rates among NTM-PD (搜索) patients.